Not Yet RecruitingPhase 4

Topical Diacerein in Psoriasis Vulgaris

Egypt60 participantsStarted 2026-02-01

Plain-language summary

The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group. Participants will: Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months. Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years old of both genders. * Patients with mild chronic plaque psoriasis body surface area (BSA \< 10%) along with Psoriasis Area and Severity Index (PASI) score of \< 10, and/or Dermatology Life Quality Index (DLQI) score of \<10. Exclusion Criteria: * Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation. * Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks. * Patients with pustular psoriasis. * Pregnant and breast-feeding individuals. * Patients with psoriatic arthritis.

What they're measuring

Proportion of Participants Achieving PASI 75

Timeframe: Week 8

Trial details

NCT IDNCT07352306

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02-01

Contact for this trial

Alaa A Helal, BSc in Pharmacy

1124438381 alaa.ashraf.muhammad@std.pharma.cu.edu.eg

View on ClinicalTrials.gov More Psoriasis Vulgaris trials